Corline Biomedical Investor Relations Material

Corline Biomedical AB is a Swedish biotechnology company focused on developing heparin-based medical solutions to improve outcomes in kidney transplantation and cell therapies. The company’s proprietary Corline Heparin Conjugate (CHC) technology is central to its product offerings. Key products include Renaparin, aimed at improving kidney transplantation by reducing complications during surgery, and Cytoparin, designed for cell therapy applications, particularly in the treatment of type 1 diabetes. The company is headquartered in Uppsala, Sweden, and its shares are listed on the Stockholm Stock Exchange.